IMMUNE THROMBOCYTOPENIC PURPURA
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited cells take aim at incurable blood diseases
Disease control Not yet recruitingThis early-stage trial tests a new treatment called CTX112 for adults with two serious autoimmune blood diseases—immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA)—that have not responded to standard therapies. CTX112 uses CRISPR gene editing to create don…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
Fatigue in ITP: is poor fitness the hidden cause?
Knowledge-focused Not yet recruitingThis study looks at whether children, teens, and young adults (ages 8–25) with chronic immune thrombocytopenic purpura (ITP) have lower aerobic fitness than healthy peers. Researchers will measure oxygen use during exercise and link it to fatigue and quality of life. The goal is …
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated May 17, 2026 05:33 UTC
-
AI tool aims to predict heart risks in rare blood disorder patients
Knowledge-focused Not yet recruitingThis study will develop an artificial intelligence (AI) tool to help doctors decide the best heart treatment for people who have both immune thrombocytopenia (ITP) and coronary artery disease. Researchers will analyze data from 600 patients to predict the risk of major heart prob…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Sponsor: Xiao Hui Zhang • Aim: Knowledge-focused
Last updated May 07, 2026 18:39 UTC